Healthy Living After Stroke: An Online Intervention For Improving Stroke Survivor Health Behaviours And Quality Of Life
Funder
National Health and Medical Research Council
Funding Amount
$590,958.00
Summary
This study will test whether an online healthy lifestyles program helps survivors of stroke to live healthier lives, improve their quality of life and prevent a second stroke.
TRIP Fellowship: Bridging The Evidence Practice Gap In Secondary Prevention In Stroke
Funder
National Health and Medical Research Council
Funding Amount
$146,247.00
Summary
Various medications have been shown to reduce the risk of recurrent vascular disease after stroke. This study aims to improve the frequency of use of these medications in patients discharged from hospital after a stroke.
Shared Team Approach Between Nurses And Doctors For Improved Risk Factor Management (STAND FIRM)
Funder
National Health and Medical Research Council
Funding Amount
$1,945,676.00
Summary
There are many proven treatments for preventing people with stroke from having a recurrent event, e.g. maintaining blood pressure at acceptable levels. However, uptake of therapies is poor. We will assess whether patients receiving individualised management plans, prepared and administered by both doctors and nurses will have risk factors controlled better than those receiving usual care. The plan includes education of patients to help them have more control over their own care.
Stroke In Australia: Understanding Variation In Clinical Care And Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
Stroke is the major cause of death and disability. My ECF research project is designed to identify (1) factors that influence hospital readmissions (2) gaps in hospital care for specific groups who experience stroke using the largest national dataset (40+ hospitals, 17,000+ patients). These data will provide evidence for me to develop and test novel future interventions to reduce inequalities in health care access in order to reduce deaths and disability through improvements in stroke care.
Kidney Function And The Effectiveness And Safety Of Direct Oral Anticoagulants In Atrial Fibrillation: The KODIAK-AF Study
Funder
National Health and Medical Research Council
Funding Amount
$451,730.00
Summary
The direct oral anticoagulants (DOACs) are a relatively new type of drug that are used to prevent the onset of stroke among patients with atrial fibrillation (AF). While these drugs have been demonstrated to be safe and effective among AF patients, in those AF patients with chronic kidney disease (CKD), there is uncertainty as to whether these drugs are similarly safe. This program of research will study the safety profile of DOACs in patients with AF and CKD.
VITATOPS Study - A Randomised, Double-blind, Placebo-controlled Trial Of Vitamins To Prevent Stroke.
Funder
National Health and Medical Research Council
Funding Amount
$1,477,963.00
Summary
Stroke is one of the most important causes of death and long-term disability in developed countries. Hardening of the arteries (atherosclerosis) is the major cause of stroke and heart attacks. High blood pressure, high blood concentrations of cholesterol, cigarette smoking and diabetes accelerate the formation of atherosclerosis, but they do not account for all strokes and heart attacks caused by atherosclerosis. There is now increasing evidence that high blood concentrations of homocysteine, a ....Stroke is one of the most important causes of death and long-term disability in developed countries. Hardening of the arteries (atherosclerosis) is the major cause of stroke and heart attacks. High blood pressure, high blood concentrations of cholesterol, cigarette smoking and diabetes accelerate the formation of atherosclerosis, but they do not account for all strokes and heart attacks caused by atherosclerosis. There is now increasing evidence that high blood concentrations of homocysteine, a normal protein in the blood, are another major causal risk factor for atherosclerosis (and stroke and heart attacks). Furthermore, blood concentrations of homocysteine can be lowered by about one quarter with simple, safe and inexpensive multivitamin therapy (folic acid, vitamin B12, and vitamin B6). However, despite the potentially massive public health benefits of such a strategy, it remains to be demonstrated in properly designed clinical trials that lowering homocysteine levels in the blood actually prevents stroke and heart attack. The VITATOPS trial is the only ongoing randomised, double-blind, placebo-controlled trial in the world which aims to determine whether multivitamin therapy (folic acid 2 mg, vitamin B12 0.5 mg, and vitamin B6 25 mg) prevents recurrent stroke and heart attacks in patients who have suffered a recent stroke.Read moreRead less
A Longitudinal Investigation Of The Efficacy Of Pharmacological Smoking Cessation Aids In Real-life Settings
Funder
National Health and Medical Research Council
Funding Amount
$592,837.00
Summary
Currently around 3 million Australians, or 17% of people aged 14 years and over, smoke tobacco daily. These smokers are at major risk of developing coronary heart disease, stroke, peripheral vascular disease, and a variety of cancers, including lung, laryngeal, oral, kidney, bladder, breast, pancreas and colon cancers. At any one time almost half of Australian smokers intend to quit smoking or have already set a date to do so but few (around 10%) succeed on each attempt. Clinical trials of quitt ....Currently around 3 million Australians, or 17% of people aged 14 years and over, smoke tobacco daily. These smokers are at major risk of developing coronary heart disease, stroke, peripheral vascular disease, and a variety of cancers, including lung, laryngeal, oral, kidney, bladder, breast, pancreas and colon cancers. At any one time almost half of Australian smokers intend to quit smoking or have already set a date to do so but few (around 10%) succeed on each attempt. Clinical trials of quitting aids, such as nicotine patches, gum and Zyban, suggest that smokers are around twice as likely to quit if using these. However clinical trials are conducted in artificial environments and these quitting aids appear to have a far smaller impact on successful quitting rates in the 'real world'. Pharmaceutical quitting aids are heavily advertised by drug companies and widely used in Australia. Futhermore the Commonwealth Government has invested over $133 million dollars subsidising such aids to Australian smokers in the past four years. However it is not known to what extent these quitting aids have made a difference to Australian smoking rates. Sales volumes of pharmaceutical quitting aids appear not to have translated into expected increases in numbers of smokers successfully quitting, suggesting they are less effective than clinical trials suggest. The present study aims to investigate whether pharmaceutical quitting aids actually are less effective in the 'real world', and if so, why.Read moreRead less
VITATOPS Study - A Randomised, Double-blind, Placebo-controlled Trial Of Vitamins To Prevent Stroke.
Funder
National Health and Medical Research Council
Funding Amount
$470,887.00
Summary
The VITAmins To Prevent Stroke (VITATOPS) trial is the only ongoing randomised, double-blind, placebo-controlled trial in the world which aims to determine whether multivitamin therapy (folic acid 2 mg, vitamin B12 0.5 mg, and vitamin B6 25 mg) prevents recurrent stroke and heart attacks in patients who have suffered a recent stroke. To date more than 7,500 patients have been randomised. Ongoing support is requested to complete the follow-up of 8,000 patients by middle of 2009.
Does Pneumococcal Vaccination Protect Against Cardiovascular Disease? A Randomised Placebo-controlled Double Blind Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,849,245.00
Summary
Australian researchers have set up a novel multi-centre trial to investigate the effects of the pneumococcal vaccination in reducing heart attacks and stroke. People aged 55 to 61 from 6 sites around Australia will be invited to participate in the study. The selected participants will attend a clinic in their area and will be randomly given the pneumococcal vaccine or a placebo vaccine. Outcomes on the expected 6000 participants will be ascertained by health record linkage with government databa ....Australian researchers have set up a novel multi-centre trial to investigate the effects of the pneumococcal vaccination in reducing heart attacks and stroke. People aged 55 to 61 from 6 sites around Australia will be invited to participate in the study. The selected participants will attend a clinic in their area and will be randomly given the pneumococcal vaccine or a placebo vaccine. Outcomes on the expected 6000 participants will be ascertained by health record linkage with government databases after 4 years.Read moreRead less